Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
In part 5 of this Exclusive Interview, Todd Hobbs talks with Diabetes in Control Publisher Steve Freed about the overall results of the Confirm real-world study.
Todd Hobbs is vice president and US Chief Medical Officer for Novo Nordisk.
Transcript of this video segment:
Steve Freed: Let’s go to the Confirm study, what are the high level results of that?
Todd Hobbs: So the Confirm study is really, I would say an exciting interesting study because it’s real world in nature, and we know that this past year our randomized clinical trial, DEVOTE, which was a blinded study against Glargine U-100, showed very positive results that are now on the label in regards to reducing the risk of severe hypoglycemia versus Glargine. But this is the real world and we often get questions from clinicians, payers, even patients. How does this work in the real world and how is it gonna work for me or how is it going to work in our clinic? So this is over 4,000 patients that were studied in a retrospective fashion, but in looking at a real world fashion comparing versus actually U-300 or Toujeo versus Tresiba. And it did show that those individuals who came in that needed insulin intensification that went on either U-300 Toujeo or U-100 Tresiba, that they could do so and have less risk of hypoglycemia with U-100 Tresiba while actually achieving a difference in A1c, a lower A1c or a greater reduction I A1c. And this was done throughout several different data sets that EHRs capture in the U.S. and again in over a year’s time.
Steve Freed: The results are encouraging, to get the patient to stay on treatment?
Todd Hobbs: Yes. So we did see an improvement in adherence too, and we’ve heard that and but it’s always nice to try to investigate data that if we can really get patients to goal but then hopefully they’ll stay on their therapy, and we hear that some of the features of Tresiba, with being able to dose any time of the day, are making that easier for patients to really maintain on therapy, which we know is a key that we stop taking your therapy no matter what it is, then you’re kind of back to the drawing board and have to start again. So we’re encouraged by the adherence and the positive response.